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Introduction
Three decades have passed since seminal discoveries 
demonstrated a causal link between the ras genes 
harbored in murine sarcoma retroviruses and cancer 
pathogenesis [1]. In this time, the RAS gene products, 
the GTPases, H-Ras, N-Ras and K-Ras 4B/4A, have been 
recognized as key signal transducers. The mechanisms 
whereby Ras is regulated by guanine‐nucleotide exchange 
factors (GEFs) and GTPase-activating proteins (GAPs) 
have been elucidated. In addition, the constituents of 
the main effector pathways through which Ras relays 
its signals to the interior of the cell have been identified 
and the distinct actions of Ras signals in different 
cellular microenvironments are being investigated [2,3]. 
The unraveling of these biochemical milestones has 
progressed in parallel to the acquisition of a broad 
knowledge of the role of Ras in cancer. Since the early 
1980s, during which HRAS was identified as the first 
human oncogene and its activating mutations were 
defined, mutant alleles of the three RAS genes have 
been detected in many human cancers. Analysis of 
more than 40,000 tumor samples indicates an activating 
mutation rate of 22, 8.2 and 3.7% for KRAS, NRAS and 
HRAS, respectively [4]. If cases in which mutational 
activation is detected (in most cases in a non-overlapping 
occurrence) in components of Ras effector pathways 
are considered, namely BRAF (22%) and p110α PI3K 
(12%), the proportion of human neoplasia exhibiting a 
hyperactive Ras-related pathway is greater than 50% 
[5,6]. In addition, a vast body of data has been gathered 
substantiating the importance of Ras signals in cancer 
initiation and progression. Activated mutants of Ras or 
of its downstream effectors have been demonstrated to 
induce malignant transformation in many cell types, as 
a result of unregulated proliferation, differentiation or 
survival [1]. Pharmacological and genetic inhibition of 
Ras signals have demonstrated the role of this protein 
in the activation and maintenance of the transformed 
phenotype [2,4]. In addition, sophisticated animal 
models have supported the importance of Ras and its 
downstream routes for tumorigenesis in vivo [7]. 
As a result, it is not surprising that Ras has attracted 
enormous attention, both in academia and industry, for 
its potential as a target in cancer therapy. Large amounts 
of research have been dedicated to strategies directed 
at curtailing Ras aberrant signals as a means of halting 
tumor progression. Most of these initiatives have been 
aimed at either inactivating Ras or inhibiting the activity 
of some of its downstream kinases. The results have 
been mixed. The attempts to inactivate oncogenic 
Ras have been mostly unsuccessful [8-10]. In the case 
of the approaches toward inhibiting downstream 
kinases, mostly directed against Raf and MEK family 
kinases, several generations of inhibitors have been 
under investigation. Some inhibitors have advanced 
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through clinical trials, but most have been hampered 
by poor clinical efficacy and/or undesired toxic effects [11].
Research to identify alternative approaches to target 
Ras signals to enable the generation of more efficient 
and less toxic inhibitors is ongoing. New data have 
unveiled a plethora of proteins and processes that have 
critical regulatory roles in Ras signaling. Moreover, novel 
functional interactions have been identified, introducing 
new players into Ras-regulated pathways that could 
provide potential new targets for therapeutic intervention. 
This review presents an overview of these novel findings 
that could provide new approaches for interfering with 
Ras signals.
Old drugs for old concepts
Since it was determined that amino acid substitutions 
at codons 12, 13 and 61 impaired Ras GTPase activity, 
making it unresponsive to GAPs, substantial efforts 
were devoted to identify approaches to restore Ras 
enzymatic activity; thus far, this research has been 
unsuccessful [12,13]. As an alternative strategy, Ras 
access to the plasma membrane (PM), which is essential 
for the biological activity of Ras [14], was inhibited using 
farnesyltransferase inhibitors. These studies yielded 
positive results in mouse models of H-Ras; however, 
these results were not replicated in clinical trials 
[4], likely because K-Ras and N-Ras, unlike  H-Ras, 
are also modified by geranylgeranylation, a process 
that increases in activity when farnesylation is 
blocked (for a review, see reference [15]). Combined 
inhibition of farnesylation and geranylgeranylation 
demonstrated high toxicity in preclinical studies, and 
was not considered to be a viable option [9]. Other 
attempts to inhibit Ras activity included the blockade 
of Ras expression using antisense oligonucleotides [16], 
but this strategy has not been successful because of 
the high level of specificity of these molecules and the 
difficulty of delivery to the target tumors [17]. Another 
approach has been the use of inhibitors of prenylated 
protein methyltransferase (PPMTase), the enzyme that 
methylates Ras proteins. PPMTases inhibit Ras-dependent 
cell growth by an unknown mechanism that is probably 
unrelated to the inhibition of Ras methylation [18]. 
The most potent of these inhibitors, S-trans,trans-
farnesylthiosalicylic acid (FTS) (salirasib, Concordia 
Pharmaceuticals), has undergone phase I trials for 
solid tumors with promising results [19] (Table 1); 
however, Ras remains a difficult molecule to target 
pharmacologically.
Raf inhibitors
The difficulties experienced with developing Ras 
inhibitors have resulted in a shift in focus to several 
downstream kinases of Ras pathways, particularly those 
kinases that form the cascade leading to the activation 
of ERK MAP kinases [4] (Figure 1). The Raf kinase family 
(ie, ARaf, BRaf and cRaf) has emerged as an appealing 
target, after the discovery of activating mutations in 
BRAF in 60% of melanomas, 40% of thyroid tumors, and 
20% of colorectal and ovarian tumors [20,21]. In addition 
to sorafenib (Nexavar) [22,23], which is approved for 
the treatment of hepatocellular and renal cell carcinoma, 
three Raf inhibitors are being evaluated in clinical 
trials: RAF-265 (Novartis; ClinicalTrials.gov identifier: 
NCT00304525); vemurafenib (Plexxikon/F Hoffman-La 
Roche) [24] and XL-281 (Bristol-Myers Squibb; 
NCT00451880 and NCT01086267; for reviews, see 
references [11,25]) (Table 1). These inhibitors function 
as ATP-competitive analogs that, by definition, exhibit 
some degree of unspecificity. Thus, doubts remain as to 
whether the antitumoral effects of these agents are a 
result of off-target effects or their anti-Raf activity. Such 
is the case for sorafenib, which also inhibits VEGF-2, 
VEGF-3 and PDGFβ; the anti-oncogenic properties of this 
agent are independent of its inhibitory effect on BRaf 
[26]. Another caveat is that tumors tend to acquire 
resistance to these inhibitors, probably as a result 
of 'gatekeeper' mutations. For example, resistance 
to vemurafenib is developed in a median time of 8 to 
9 months of treatment [27]. Of major concern are 
recent discoveries demonstrating that Raf inhibitors 
can have opposite effects to those intended, depending 
on the cellular context. In tumors harboring oncogenic 
K-Ras mutations, Raf inhibitors promote ERK activation 
in a Ras-dependent manner, with subsequent stimulation 
of tumor growth [28,29]. Similarly, a dead-kinase mutant 
of BRaf and oncogenic K-Ras cooperate to induce 
melanoma in mice [30]. These results highlight the need 
for screening patients for BRaf and Ras mutations in 
order to distinguish those patients likely to respond 
from those in which anti-Raf therapies could be 
harmful. Importantly, these adverse interactions also 
reduce the therapeutic options available to treat the 
large number of tumors harboring Ras mutations.
MEK kinase inhibitors
Inhibitors of MEK kinases (MEK1 and MEK2) are also 
available as a therapeutic option. Unlike Raf inhibitors, 
MEK kinase inhibitors are not ATP mimetics and, 
consequently, exhibit high specificity. The mode of 
action of MEK kinase inhibitors results from binding to a 
unique inhibitor-binding pocket, locking the kinase in a 
closed, inactive form [31]. PD-184352 (Pfizer) [32,33], 
PD-0325901 (Pfizer) [25,34], AZD-6244 (AstraZeneca) 
[35] and XL-518 (Genentech/Exelixis; NCT00467779) 
have undergone clinical trials (Table 1). PD-184352 
demonstrated insufficient clinical activity, but its positive 
safety profile has encouraged the development of 
derivatives [32]. The development of PD-0325901 was 
discontinued because of toxicity concerns [25,36]. 
AZD-6244 has completed phase I trials in patients 
with advanced cancer [37] and is in phase II trials 
in combination with other chemotherapeutic agents, 
including sorafenib and PI3K inhibitors, following 
promising results in mouse models [38,39]. XL-518 
has been reported to inhibit ERK1/2 activation in a 
preclinical xenograft model and to be well tolerated in 
a phase I trial [40]. The development of resistance is 
also a concern for MEK inhibitors. Screening of tumors 
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Table 1. Drugs targeting Ras-regulated pathways.
Compound
(developing company)
Target Tumor type Highest 
development status
Reference
Salirasib
(Concordia Pharmaceuticals)
Ras Solid tumor
NSCLC
Phase II [19]
Sorafenib Raf, PDGFRβ, VEGFR-2/3, 
c-KIT and FLT-3
Advanced renal cell carcinoma
Advanced hepatocellular carcinoma
Launched [22,23]
vemurafenib (Plexxikon/ 
F Hoffman-La Roche)
Mutant BRaf Melanoma
Colorectal tumor
Solid tumor
Phase III [98]
XL-281
(Bristol-Myers Squibb)
All Raf isoforms and 
mutant BRaf
Advanced solid tumor Phase I NCT00451880 and 
NCT01086267
RAF-265 (Novartis) Raf and VEGFR Advanced melanoma Phase I NCT00304525
PD-184352 MEK1/2 Colon cancer
Pancreatic cancer
Breast cancer
NSCLC
Discontinued [32,33]
PD-0325901 MEK1/2 Advanced solid tumor
Breast cancer
Colon cancer
Melanoma
Discontinued [11,34]
AZD-6244
(AstraZeneca)
MEK1/2 Advanced melanoma
Biliary cancer
Pancreatic cancer
NSCLC
Advanced colon cancer 
Hepatocellular carcinoma
Thyroid tumor
Solid tumor
Phase II [35]
XL-518
(Genentech/Exelixis)
MEK1/2 Solid tumor Phase I NCT00467779
GDC-0941
(Genentech)
Class I PI3K Advanced solid tumors
Breast tumors
Non-Hodgkin's lymphoma
Phase I NCT00876122, 
NCT00960960 
and NCT00996892 
MK-2206
(Merck & Co)
AKT Advanced solid tumors Phase II NCT01071018 and 
NCT01186705
Perifosine
(Keryx Biopharmaceuticals/
AEterna Zentaris/Handok 
Pharmaceuticals)
AKT Advanced solid tumors
Melanoma
Multiple myeloma
Renal cell carcinoma
Leukemia
Sarcoma
Phase III [52]
NCT01002248
Everolimus mTORC1 Soft-tissue and bone sarcoma
Advanced solid tumors
Brain tumor
Head and neck cancer
Breast cancer
Prostate cancer
Launched [56,99]
Temsirolimus mTORC1 Advanced renal cell carcinoma
Advanced solid tumors
Myeloma
NSCLC
Endometrial cancer
Launched [53,54,100]
from relapsed patients following AZD-6244 treatment 
detected mutations in MEK that conferred resistance to 
the inhibitor [41]. Resistance also can develop in the 
absence of mutations in MEK itself, probably as a result 
of alterations in other key regulatory molecules. For 
example, K-Ras activation has been demonstrated to 
confer resistance to PD-184352 [42]. Notably, mutations 
activating the PI3K pathway are a major resistance 
mechanism for MEK inhibitors in tumors harboring wild-type 
MEK [43].
PI3K inhibitors
The available pharmacological agents that target 
Ras-mediated signals are not restricted to the Raf-ERK 
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pathway. The PI3K pathway has also been the subject of 
significant research. Ras-GTP interacts with the p110α 
and p110β catalytic subunits of PI3K, activating a 
pathway that generates a strong anti-apoptotic and 
pro-proliferative signal (Figure 1). The PI3K pathway 
is negatively regulated by the phosphatase PTEN [44]. 
Different components of the PI3K signaling pathway 
are deregulated in cancer. The loss of PTEN functions 
occurs in 30 to 40% of tumors [5], resulting in the 
maintenance of the downstream kinase AKT in a 
hyperactive state. Gain-of-function mutations have also 
been detected in p110α, and amplifications are frequent in 
the geneencoding p110β [45]. Finally, somatic mutations 
and amplifications of the AKT family genes have also 
been reported [46]. Unlike the Raf pathway, overlapping 
mutations in different components of the PI3K pathway 
can occur depending on the tumor type [47]: in 
endometrial cancers, Ras and PI3K mutations are 
mutually exclusive, suggesting that p110α is not 
necessary for the initiation of these tumors. Conversely, 
concomitant mutations of Ras and p110α are observed 
in 7% of colorectal cancers, indicating that these 
oncogenes synergize to confer a selective advantage in 
these cells [48]. The co-existence of such mutations is 
likely to be helpful to classify patients for treatment. A 
major concern of targeting the PI3K pathway alone 
is that this approach may not be sufficient to halt 
tumor progression. However, the use of these drugs in 
combination with treatments against other pathways 
could prove beneficial for patients with cancer.
Several inhibitors against different components of 
the PI3K pathway, such as AKT and mTOR, are under 
evaluation. LY-294002 and wortmannin were the first 
PI3K inhibitors to be used in preclinical studies. These 
inhibitors were highly unspecific and very toxic in 
animals models, but derivatives are being developed, 
some of which are in early clinical trials (eg, SF-1126 
[Semafore Pharmaceuticals] and PX-866 [Oncothyreon]) 
[49,50]. The observation that the PI3K inhibitor PI-103 
also inhibited mTOR [51] has led to the development 
of dual PI3K-mTOR inhibitors. The rationale behind 
this approach is that inhibiting both components 
concomitantly could have a stronger antitumoral effect, 
though concerns for potential severe side effects also 
exist [49]. Nevertheless, derivatives of PI-103, such as 
GDC-0941 (Genentech; NCT00876109; phase I), and 
other dual inhibitors are undergoing clinical trials 
[44]. With respect to AKT family kinases, two types 
of inhibitors have been developed: ATP-competitive 
inhibitors and non-catalytic inhibitors. Most of the 
ATP-mimetic drugs can inhibit all AKT isoforms, as well 
as other members of the AGC kinase family. For this 
reason, isoform-specific inhibitors are being developed. The 
non-catalytic inhibitors function by masking the pleckstrin 
homology domain, thereby preventing AKT binding to 
the membrane. These non-catalytic inhibitors include 
perifosine (Keryx Biopharmaceuticals/AEterna Zentaris/
Handok Pharmaceuticals) [52] and MK-2206 (Merck & 
Co; NCT01071018), which are in phase III and phase II 
clinical trials, respectively. Finally, mTOR inhibitors are 
available as cancer therapy. Rapamycin is approved for 
Figure 1. 'Classical' therapeutic targets in Ras pathways. 
A simplified representation of the Ras effector pathways harboring components with enzymatic activities that are targeted for antitumor 
therapy. Therapeutic agents in black have been discontinued. 
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the treatment of renal carcinoma [44], and several 
derivatives of this inhibitor have been developed and 
approved, such as temsirolimus [53,54] and everolimus 
[55,56]. One limitation of mTOR inhibitors is that these 
compounds can trigger the activation of PI3K through 
the inhibition of a negative feedback loop [57]. 
However, this effect may be overcome by the use of 
dual PI3K-mTOR inhibitors. 
While more of these 'classical' inhibitors of Ras pathways 
are expected to be delivered in the near future, the 
question arises whether new approaches to Ras-regulated 
pathways can be used to develop alternative types of 
drugs to inhibit aberrant signaling.
The Ras-ERK pathway: Targeting dimerization
The characteristic of ERKs to dimerize in response to 
stimulation is well known [58]; however, the biochemical 
and biological significance of ERK dimerization were 
unknown until recently, when it was demonstrated 
that ERK dimers are formed using scaffold proteins 
as dimerization platforms [59]. These scaffold-dimer 
complexes are critical for relaying the cytoplasmic 
signals of ERK, by managing the interaction of ERKs with 
their cytoplasmic substrates. In contrast, activation 
of the nuclear substrates of ERK is mostly undertaken 
by ERK monomers [59]. Importantly, the inhibition of 
the cytoplasmic component of ERK, by preventing 
ERK dimerization, is sufficient to abrogate cellular 
transformation and proliferation, as well as tumor 
formation in xenografts of lung, colorectal and bladder 
carcinoma cells in mice [59].
Dimerization seems to be a common theme in the 
ERK cascade. BRaf and cRaf heterodimerize in a 
Ras-dependent manner following stimulation [60,61], 
whereas oncogenic mutants dimerize constitutively. This 
process requires the participation of the protein 14-3-3 
and is essential for cRaf transactivation by BRaf [62]. 
Importantly, mutations that prevent dimerization of 
Drosophila Raf also impair its catalytic function [63]. 
Similarly, BRaf that cannot dimerize as a result of 
similar mutations is incapable of transactivating cRaf, 
stimulating ERK phosphorylation [28] and inducing 
transformation [64]. MEK family kinases also dimerize. 
MEK1 and MEK2 form stable heterodimers not regulated 
by growth factor stimulation. These heterodimers are 
critical for fine-tuning the amplitude and duration of 
ERK activation, by a mechanism that entails negative 
feedback regulation by ERK via phosphorylation of MEK1. 
In the absence of phosphorylated MEK1, heterodimer 
formation is prevented, and MEK2 phosphorylation and 
ERK activation are prolonged [65].
These findings highlight that the pathway leading to 
ERK activation involves much more than phosphorylation; 
critical protein-protein interactions must occur to ensure 
the propagation of the ERK signals. Some of these 
interactions offer, at least conceptually, attractive targets 
for future antitumoral drugs. The demonstration that 
inhibiting ERK dimerization by genetic means is sufficient 
for halting tumoral cell proliferation [59] and recent 
findings suggesting that inhibiting ERK dimerization 
potentiates the apoptotic effects of drugs such as 
cisplatin, paclitaxel and doxorubicin [Crespo P: unpublished 
data], has led to the screening for compounds that 
can prevent ERK dimerization. This effort has led to the 
identification of several compounds that prevent ERK 
dimerization that are undergoing further evaluation 
[Crespo P: unpublished data].
Similarly, Raf heterodimerization also demonstrates 
potential as a target for therapeutic intervention. As 
demonstrated for Drosophila Raf [63] and mammalian 
BRaf-cRaf dimers [28], preventing the formation of Raf 
dimers diminishes ERK signaling significantly. Strategies 
for impeding the association between BRaf and cRaf 
could be aimed directly at the dimerization interface, 
but also at the 14-3-3 binding sites, an essential 
interaction for dimerization to occur [62,64,66]. Unlike 
Raf and ERK dimers, MEK heterodimers appear not to 
be a suitable therapeutic target because blocking 
MEK1-MEK2 dimerization would result in enhancing ERK 
activation [65]. Importantly, dimerization interfaces and 
other protein-protein interaction motifs are probably 
unique regarding their molecular structure and 
interactions. Thus, targeting these structures could 
yield drugs with higher specificity, and subsequently less 
undesired, off-target, secondary effects, compared with 
those compounds resulting from conventional strategies 
directed at inhibiting the enzymatic activities of kinases.
Spatial regulators as therapeutic targets
Recent discoveries have established the concept that 
Ras signals are the sum of multiple, site-specified 
sub-signals [67]. Conceptually, searching for compounds 
that selectively block Ras sub-signals essential for 
tumor progression should produce drugs with reduced 
side effects, compared with compounds that block Ras 
signaling completely. It is known that within the PM, 
Ras is present at distinct microdomains [68]. In addition, 
Ras is also present in different endomembranes 
(for a review, see reference [3]). At these sites, Ras 
is subject to site-specific control mechanisms undertaken 
by various regulatory proteins (for an extensive 
review, see reference [69]). Recent studies have 
demonstrated that cellular transformation can be 
prevented/reverted by the inhibition of specific, location-
defined sub-signals. For example, transformation by 
oncogenes such as v-Src and Sis can be prevented by 
the inhibition of Ras signals generated by lipid rafts or 
disordered membrane [70]. Annexin A6, an ancillary 
protein that facilitates Ras inactivation via p120 GAP, 
suppresses Ras-induced transformation by recruiting 
p120 GAP specifically to non-raft PM microdomains [71]. 
Inhibiting Galectin-1, a protein essential to stabilize 
active H-Ras in non-raft PM 'nanoclusters', dislodges 
H-Ras from these structures and prevents fibroblast 
transformation [72]. These data illustrate that it is 
not necessary to suppress Ras signaling completely 
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in order to obtain growth/transformation-suppressive 
responses. Thus, although conceptual, strategies directed 
at modulating the functions of some of these site-specific 
regulators could be a valid therapeutic option in the 
future.
The same concept is applicable to events downstream 
from Ras. ERKs are found in the cytoplasm in unstimulated 
cells; an important fraction of ERKs migrates to the 
nucleus upon phosphorylation, where the ERKs perform 
essential functions [73]. However, the extranuclear 
component of ERK is as important; approximately half 
of the ~180 proteins identified as ERK substrates are 
non-nuclear proteins [74]. The nuclear and cytoplasmic 
components of ERKs are potential targets for antineoplastic 
therapy. Ample data demonstrate that sequestering ERKs 
at the cytoplasm, thereby impeding ERK nuclear signals, 
is sufficient for abrogating growth or provoking apoptosis 
in tumor cells [75-77]. The nucleo-cytoplasmic shuttling 
of ERKs is finely regulated. For efficient nuclear 
translocation, ERKs require direct interaction with the 
nuclear pore complex, and the participation of nuclear 
shuttles and a nuclear translocation signal, Ser-Pro-Ser, 
within the 'insert' domain, that is phosphorylated 
upon stimulation, promoting nuclear translocation 
[78]. Conceptually, drugs aimed at masking this short 
sequence could represent an option to stop the nuclear 
translocation of ERK. As mentioned previously, inhibiting 
the cytoplasmic component of ERK by disrupting its 
dimerization is sufficient to prevent tumor progression 
[59]. Thus, the blockade of either of these subcellular 
components may be a valid strategy for future 
therapeutic intervention.
The amplitude and intensity of ERK signals are regulated 
by scaffold proteins that assemble the components of 
the signaling cascade into a complex whereby signal 
optimization is achieved [79]. Scaffolds also play 
important roles in the spatial selectivity of ERK, 
operating as transmitters of Ras signals, originating at 
different microenvironments, to specific ERK substrates 
[80]. Distinct scaffolds appear to operate in different 
subcellular localizations: KSR1 regulates ERKs signals at 
PM cholesterol-rich domains [81]; MP-1 at endosomes 
[82]; Sef at the Golgi complex [83]; paxillin at focal 
adhesions [84]; and β-arrestins in clathrin-coated pits 
[85]. Scaffold proteins are candidates with enormous 
potential to become site-specific therapeutic targets. 
Some of these proteins, such as KSR1, have no known 
function other than regulating ERKs, so no off-target 
effects are expected. This specificity could make KSR1 
an ideal target for intervention. Indeed, mice deficient 
in KSR1 develop normally, but are resistant to tumor 
development [86]. Unfortunately, much important 
structural information related to ERK has not yet been 
elucidated, including how MEK and ERK dock onto KSR1. 
These sites harbor the potential to become hotspots for 
the design of drugs aimed at disrupting ERK signals 
through competitive binding to scaffolds.
The Ras apoptotic route as a therapeutic 
target
It is well known that oncogenic Ras can trigger apoptosis 
in different cell types. Recent findings involve RASSF 
family proteins as critical pro-apoptotic effectors [87,88]. 
In response to Ras activation, members of this family, 
such as RASSF1, NORE1 and RASSF2, activate the 
pro-apoptotic kinases MST1 and MST2, engaging a 
pathway through which cell survival is regulated (Figure 2) 
[89-91]. Conversely, cRaf inhibits MST2 in a kinase-
independent manner [92,93]. Thus, MST2 association 
with RASSF family proteins promotes apoptosis, 
whereas the interaction of MST2 with cRaf prevents it, 
resulting in aberrant growth. Although many aspects 
of MST1/2 regulation remain unknown, targeting MST1/2 
could be of use in the treatment of tumors harboring 
Ras, and possibly BRaf, mutations. The development of 
inhibitors for the interaction between cRaf and MST2, 
thereby shifting the balance toward MST2 association 
with RASSF, should direct tumor cells to apoptosis.
Alternative strategies to treat Ras tumors
Despite significant research efforts and investments 
devoted to the development of drugs aimed at targets 
within the Ras pathways, there has been limited success 
thus far. For this reason, new approaches are necessary. 
Recently, the concept of 'non-oncogene addiction' has 
been proposed, based on the observations that certain 
normal genes are necessary for the maintenance 
of the tumoral phenotype [94]. These genes can be 
directly regulated by an oncogene, but can also act in 
parallel pathways and, therefore, not appear as obvious 
candidates for pharmacological intervention. If these 
genes are inhibited, there is a synthetic lethality effect 
resulting in the activation of senescence or apoptotic 
responses, causing tumor regression [94]. This concept 
has been used to identify genes necessary for the 
maintenance of 'Ras-addicted' tumors. Using RNAi 
screening, PLK1, STK33, SYK, RON, TBK and integrin β6 
have been identified as essential for the progression of 
tumors harboring oncogenic Ras [95-97]. In the near 
future, more of these genes will be identified, some of 
which will have the potential to be exploited for the 
development of new antineoplastic therapies. 
Conclusion
The knowledge acquired during the past three decades 
regarding Ras and its related pathways has led to 
significant advances in tumor treatment. Unfortunately, 
many of the expectations for Ras pathway-targeted 
drugs have not been fulfilled. High toxicity and resistance 
acquisition have hampered many of the drugs developed 
to date. While more of these 'classical' inhibitors are to 
be expected, recent findings in the Ras field have 
revealed new players and novel functional interactions 
that provide an alternative approach to target Ras 
signals by focusing on protein-protein interactions rather 
than enzymatic activities. These novel findings could 
introduce a new era in drug discovery and in the 
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development of new types of drugs for the treatment 
of tumors with mutations in the Ras signaling pathways. 
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